← Back to Clinical Trials
Recruiting NCT05699525

NCT05699525 Personalized Mobile Cognitive Behavioral Therapy Application

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05699525
Status Recruiting
Phase
Sponsor Weill Medical College of Cornell University
Condition Anxiety Disorders and Symptoms
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2024-08-02
Primary Completion 2027-07

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 25 Years
Study Type INTERVENTIONAL
Interventions
Personalized MAYA Mobile AppGeneral MAYA Mobile App

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2024-08-02 with a primary completion date of 2027-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to compare the effectiveness of a standard mobile cognitive behavioral therapy program to a personalized mobile cognitive behavioral therapy program that introduces new skills over a shorter period of time. Participants will use the Maya app for two days per week, at least 20 minutes per day, for six weeks. Assessments will include a weekly check in with a member of the research team, questionnaires, and optional electroencephalographic (EEG) recordings at the beginning and end of the 6-week intervention. The investigators think that that the less burdensome personalized program will be just as effective at improving symptoms of anxiety and depression as the general program.

Eligibility Criteria

Inclusion Criteria: * Age between 18 and 25 years. * Primary diagnosis of an anxiety, depressive, or bipolar disorder as determined by a score of 4 or greater on the Clinical Severity Rating of the Anxiety Disorders Interview Schedule (ADIS). * If an individual is diagnosed with bipolar disorder, they must be currently euthymic or experiencing a depressive episode. * Access to an Apple iPhone, iPad, or Android device. Exclusion Criteria: * History of neurologic disorder that may affect the neural systems of interest or participant's ability to participate * Lifetime diagnosis of a psychotic disorder. * Current hypomanic or manic episode. * Currently in cognitive behavior therapy. * Change in dose of a psychiatric medication in the past 12 weeks. * Initiation of psychotherapy in the past 12 weeks. * Intent or plan to attempt suicide.

Contact & Investigator

Central Contact

Maddy Schier

✉ mas4019@med.cornell.edu

📞 (646) 289-5271

Principal Investigator

Jennifer Bress, Ph.D.

PRINCIPAL INVESTIGATOR

Weill Medical College of Cornell University

Frequently Asked Questions

Who can join the NCT05699525 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 25 Years, studying Anxiety Disorders and Symptoms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05699525 currently recruiting?

Yes, NCT05699525 is actively recruiting participants. Contact the research team at mas4019@med.cornell.edu for enrollment information.

Where is the NCT05699525 trial being conducted?

This trial is being conducted at New York, United States.

Who is sponsoring the NCT05699525 clinical trial?

NCT05699525 is sponsored by Weill Medical College of Cornell University. The principal investigator is Jennifer Bress, Ph.D. at Weill Medical College of Cornell University. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology